Investigational Studies

LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it has submitted its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Epidiolex® (cannabidiol or […]

by

– First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat – – Pharmaceutical formulation of cannabidiol significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic drugs – LONDON and CARLSBAD, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) — […]

by

Vitality Biopharma is seeking orphan drug designation from the U.S. Food and Drug Administration (FDA) for its targeted cannabinoid therapy, VITA-100, for the treatment of pediatric ulcerative colitis. The FDA grants orphan drug status to promising treatments for rare diseases affecting fewer than 200,000 people per year in the United States. Upon approval, the designation is expected […]

by

LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it has submitted its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Epidiolex® (cannabidiol or […]

by